Primary Care Diabetes Prescriptions Cost UK Over £2 Million a Day
Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).
Prescriptions to manage diabetes in primary care in the UK cost the NHS an average of £2.2 million ($3.7 m) every day in 2013-14, according to a report from the Health and Social Care Information Centre (HSCIC).
The report, Prescribing for Diabetes, also shows the Net Ingredient Cost (NIC) for managing diabetes was £803.1 million ($1,347 m) in 2013–14. This is a 5.1 per cent increase from £764.1 million in 2012–13 (£2.1 million per day on average) and a 56.3 per cent increase on £2005-06 (£1.4 million per day on average).
Almost 10 per cent (9.5 per cent) of the NHS’s total primary care drugs bill was spent on managing diabetes, revealing a continuous annual rise from 6.6 per cent in 2005–06.
THe HSCIC report shows that in primary care in 2013-14:
- There were 45.1 million prescription items for managing diabetes, an average of 123,610 items per day.
- Insulin items can be prescribed for both type 1 and type 2 diabetes and accounted for about one in seven items prescribed for diabetes.
- Seven out of ten diabetes prescription items were for anti diabetic drugs, which are prescribed only for type 2 diabetes.
- Diagnositic and monitoring devices made up the remainder of diabetes items prescribed and the majority of these were blood glucose testing strips.
- Costs of all three categories of diabetes drugs have increased from 2005-06 but in particular insulin items where the rise in spending was 11.6 per cent higher than the rise in items prescribed.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.